{
    "organizations": [],
    "uuid": "7c15da1538cab13782e6aeec20bc1b863fb7d582",
    "author": "",
    "url": "https://www.reuters.com/article/brief-catabasis-pharmaceuticals-presents/brief-catabasis-pharmaceuticals-presents-new-edasalonexent-data-idUSFWN1S21AJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Catabasis Pharmaceuticals Inc:\n* CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT\n* CATABASIS PHARMACEUTICALS INC - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MRI T2 RATE OF CHANGE Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-26T00:08:00.000+03:00",
    "crawled": "2018-04-26T00:23:07.032+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "catabasis",
        "pharmaceutical",
        "inc",
        "catabasis",
        "pharmaceutical",
        "present",
        "new",
        "edasalonexent",
        "data",
        "showing",
        "significantly",
        "slowed",
        "duchenne",
        "muscular",
        "dystrophy",
        "disease",
        "progression",
        "measured",
        "mri",
        "one",
        "year",
        "treatment",
        "catabasis",
        "pharmaceutical",
        "inc",
        "statistically",
        "significant",
        "improvement",
        "mri",
        "t2",
        "rate",
        "change",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}